Dianthus Therapeutics, Inc. (DNTH)
(Delayed Data from NSDQ)
$20.39 USD
-0.85 (-4.00%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $20.38 -0.01 (-0.05%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
DNTH 20.39 -0.85(-4.00%)
Will DNTH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DNTH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DNTH
Seer, Inc. (SEER) Reports Q2 Loss, Beats Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates
DNTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates
Dianthus Therapeutics, Inc. (DNTH) Soars 6.1%: Is Further Upside Left in the Stock?
Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains?
Other News for DNTH
Commit To Buy Dianthus Therapeutics At $12.50, Earn 26.6% Annualized Using Options
Dianthus (DNTH) Price Target Raised by Guggenheim Ahead of Key Trial
Dianthus price target raised by $8 at Guggenheim, here's why
Dianthus initiated with bullish view at William Blair, here's why
Dianthus Therapeutics (DNTH) Receives Outperform Rating by William Blair | DNTH Stock News